Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;18(1):33-42.
doi: 10.1007/s10120-014-0397-4. Epub 2014 Jul 4.

Vascular endothelial growth factor a inhibition in gastric cancer

Do Joong Park  1 , Nicholas J Thomas, Changhwan Yoon, Sam S Yoon
Affiliations
Review

Vascular endothelial growth factor a inhibition in gastric cancer

Do Joong Park et al. Gastric Cancer. 2015 Jan.

Abstract

Angiogenesis is a vital process in the progression and metastasis of solids tumors including gastric adenocarcinoma. Tumors induce angiogenesis by secreting proangiogenic molecules such as vascular endothelial growth factor A (VEGF-A), and VEGF-A inhibition has become a common therapeutic strategy for many cancers. Several drugs targeting the VEGF-A pathway have been approved for clinical use in selected solid tumors, and several anti-VEGF-A strategies have been examined for gastric cancer. Phase II studies suggested that bevacizumab, an anti-VEGF antibody, can increase the efficacy of chemotherapy for advanced gastric cancer, but two international phase III trials failed to show an overall survival benefit. Two more recent international phase III trials have examined ramucirumab, an antibody targeting the primary receptor for VEGF-A, as second-line therapy for advanced gastric cancer and found a survival benefit both as single agent therapy and when combined with chemotherapy. Finally, correlative science studies suggest that the VEGF-A pathway may have varying importance in gastric cancer progression depending on ethnicity or race. This article will review the preclinical and clinical studies on the role of the VEGF-A pathway inhibition in gastric cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Exp Mol Med. 2013 Nov 01;45:e52 - PubMed
    1. Invest New Drugs. 2011 Dec;29(6):1449-58 - PubMed
    1. Nat Med. 2001 Sep;7(9):987-9 - PubMed
    1. World J Gastroenterol. 2014 Apr 28;20(16):4483-90 - PubMed
    1. Eur J Cancer. 1998 Dec;34(13):2041-5 - PubMed

MeSH terms

Substances

LinkOut - more resources